secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001437749-26-004542
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals amends CEO Bitterman's contract: severance to 12 months, bonus target to 50%
--------------------------------------------------------------------------------

- CEO Robert J. Bitterman's severance increased to 12 months base salary on termination without cause or for good reason.
- Annual target bonus opportunity raised from 40% to 50% of base salary.
- Amendment effective Feb 17, 2026; equity vesting acceleration unchanged.
- No other changes to existing employment agreement terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926004542/0001437749-26-004542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926004542/phio20260216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-004542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer